Microbion Corporation, a Montana-based pharmaceutical company focused on development of novel
therapeutics for treatment of bacterial infections, announced today that it has initiated a Phase 1 clinical
trial of the company’s lead topical anti-infective drug product. The double-blind randomized, placebo
controlled study is being conducted at clinical sites in the United Kingdom and will assess safety,
tolerability, and pharmacokinetics…
Download Full Press Release – Microbion Corporation Press Release (07.05.11)